Studies performed on immuno-competent murine models, xenotransplants and clinical samples, strongly suggest blocking of IL-30, produced by cancer and myeloid cells in the tumor and draining LNs, as a strategy to boost immunotherapy, in selected clinical cases. Here, IL27 is linked to cancer.